Abstract:

Objective To study the efficacy and safety of remimazolam tosilate in painless daytime hysteroscopic surgery. Methods A total of 300 patients （18 ~ 60 years， BMI 18.5 ~ 27 kg/m²， and ASA Ⅰ-Ⅱ） undergoing selected painless daytime hysteroscopic surgery were randomized into two groups. Group R received remimazolam tosilate at an initial dose of 0.2 mg/kg， and then single 0.05 mg/kg if needed according to bispectral index. Group P， according to the bispectral index， received propofol at an initial dose of 1.5 ~ 2 mg/kg， and single 0.5 mg/kg if needed. All the patients were intravenously given 5 μg sufentanil five minutes before hysteroscopy. The anesthesia-related indicators （anesthesia onset time， surgical duration， anesthesia recovery time， and time to leaving the operating room） and safety indexes （hypotension， hypoxia， nausea and vomiting， and doctor and patient satisfaction） were recorded. Results The incidence of hypotension and injection pain was significantly higher in group P （P < 0.01）. There were no significant differences between the two groups in surgical duration， awakening time， time to leaving the operating room， nausea and vomiting， and patient satisfaction （P > 0.05）. Conclusion Remimazolam can be used safely and effectively in painless daytime hysteroscopic surgery.

Key words: daytime surgery, remimazolam tosilate, propofol, hysteroscopy, injection pain, hypotension